secwatch.observer — SEC 8-K summary
======================================

Issuer:     Semnur Pharmaceuticals, Inc. (SMNR)
CIK:        0001913577
Form:       8-K
Filed at:   2026-03-17T23:59:59+00:00
Accession:  0001193125-26-110816
Event type: leadership
Sentiment:  neutral
Materiality: 0.75
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

CEO Jaisim Shah retires; Henry Ji appointed CEO and President; Stephen Ma named COO
--------------------------------------------------------------------------------

- Jaisim Shah resigned as CEO, President, and director effective March 13, 2026; retirement not due to any disagreement.
- Henry Ji (age 61), formerly Executive Chairperson, appointed CEO and President; also CEO of Scilex (SCLX) and Vivasor.
- Stephen Ma, previously CFO and Secretary, appointed COO effective March 17, 2026; also COO of Scilex.
- Shah receives six months base salary ($1,250,000/yr) and 90-day extension to exercise vested stock options per separation agreement.
- Board size reduced from six to five directors following Shah's resignation.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1913577/000119312526110816/0001193125-26-110816-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1913577/000119312526110816/smnr-20260313.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-110816

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer